Abstract
Gliomas are the most malignant and aggressive form of brain tumors, and account for the majority of brain cancer related deaths. Malignant gliomas, including glioblastoma are treated with radiation and temozolomide, with only a minor benefit in survival time. A number of advances have been made in understanding glioma biology, including the discovery of cancer stem cells, termed glioma stem cells (GSC). Some of these advances include the delineation of molecular heterogeneity both between tumors from different patients as well as within tumors from the same patient. Such research highlights the importance of identifying and validating molecular markers in glioma. This review, intended as a practical resource for both clinical and basic investigators, summarizes some of the more well-known molecular markers (MGMT, 1p/19q, IDH, EGFR, p53, PI3K, Rb, and RAF), discusses how they are identified, and what, if any, clinical relevance they may have, in addition to discussing some of the specific biology for these markers. Additionally, we discuss identification methods for studying putative GSC’s (CD133, CD15, A2B5, nestin, ALDH1, proteasome activity, ABC transporters, and label-retention). While much research has been done on these markers, there is still a significant amount that we do not yet understand, which may account for some conflicting reports in the literature. Furthermore, it is unlikely that the investigator will be able to utilize one single marker to prospectively identify and isolate GSC from all, or possibly, any gliomas.
Similar content being viewed by others
References
Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820
Phillips HS et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173
Verhaak RG et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98–110
Freije WA et al (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64(18):6503–6510
Parsons DW et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812
McNamara MG, Sahebjam S, Mason WP (2013) Emerging biomarkers in glioblastoma. Cancers 5(3):1103–1119
Alentorn A et al (2015) Molecular profiling of gliomas: potential therapeutic implications. Expert Rev Anticancer Ther 15(8):955–962
Cohen AL, Colman H (2015) Glioma biology and molecular markers. Cancer Treat Res 163:15–30
Tanwar MK, Gilbert MR, Holland EC (2002) Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62(15):4364–4368
Patel M et al (2012) Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opin Investig Drugs 21(9):1247–1266
Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003
Gupta K, Salunke P (2012) Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol 138(12):1971–1981
Nakagawachi T et al (2003) Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene 22(55):8835–8844
Riemenschneider MJ et al (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120(5):567–584
Horbinski C et al (2012) Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas. Neuro Oncol 14(6):777–789
Ichimura K et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341–347
Yan H et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773
Balss J et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602
Yip S, Iafrate AJ, Louis DN (2008) Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol 67(1):1–15
Sugawa N et al (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87(21):8602–8606
Nathanson DA et al (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343(6166):72–76
Karsy M et al (2015) A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus 38(3):E4
Mao H et al (2012) Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Investig 30(1):48–56
Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21–35
Nikiforova MN, Hamilton RL (2011) Molecular diagnostics of gliomas. Arch Pathol Lab Med 135(5):558–568
Lam PY et al (2000) Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme. Br J Neurosurg 14(1):28–32
Cancer Genome Atlas Research (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455(7216):1061–1068
Aldape K et al (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 129(6):829–848
Knobbe CB, Reifenberger J, Reifenberger G (2004) Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 108(6):467–470
Schindler G et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405
Jones DT et al (2009) Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28(20):2119–2123
Beier D, Schulz JB, Beier CP (2011) Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol Cancer 10:128
Cho DY et al (2013) Targeting cancer stem cells for treatment of glioblastoma multiforme. Cell Transplant 22(4):731–739
Seymour T, Nowak A, Kakulas F (2015) Targeting aggressive cancer stem cells in glioblastoma. Front Oncol 5:159
Lathia JD et al (2015) Cancer stem cells in glioblastoma. Genes Dev 29(12):1203–1217
Hemmati HD et al (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100(25):15178–15183
Bradshaw A et al (2016) Cancer stem cell hierarchy in glioblastoma multiforme. Front Surg 3:21
Trepant AL et al (2015) Identification of OLIG2 as the most specific glioblastoma stem cell marker starting from comparative analysis of data from similar DNA chip microarray platforms. Tumor Biol 36(3):1943–1953
Dahlrot RH et al (2013) What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol 6(3):334–348
Bao S et al (2008) Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 68(15):6043–6048
Yanagisawa M (2011) Stem cell glycolipids. Neurochem Res 36(9):1623–1635
Lagadec C et al (2014) The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. Stem Cells 32(1):135–144
Lathia JD et al (2010) Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6(5):421–432
Shmelkov SV et al (2005) AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37(4):715–719
Schmohl JU, Vallera DA, CD133, selectively targeting the root of cancer. Toxins, 2016. 8(6)
Singh SK et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18):5821–5828
Singh SK et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401
Irollo E, Pirozzi G (2013) CD133: to be or not to be, is this the real question? Am J Transl Res 5(6):563–581
Xia CL et al (2003) A2B5 lineages of human astrocytic tumors and their recurrence. Int J Oncol 23(2):353–361
Auvergne RM et al (2013) Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep 3(6):2127–2141
Chen J et al (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412):522–526
Lendahl U, Zimmerman LB, McKay RD (1990) CNS stem cells express a new class of intermediate filament protein. Cell 60(4):585–595
Xie L et al (2015) Characterization of nestin, a selective marker for bone marrow derived mesenchymal stem cells. Stem Cells Int 2015:762098
Kastan MB et al (1990) Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 75(10):1947–1950
Storms RW et al (1999) Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA 96(16):9118–9123
Douville J, Beaulieu R, Balicki D (2009) ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 18(1):17–25
Munakata K et al., Cancer stem-like properties in colorectal cancer cells with low proteasome activity. Clin Cancer Res, 2016
Vlashi E et al (2009) In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 101(5):350–359
Lagadec C et al (2014) Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. BMC Cancer 14:152
Donnenberg VS, Donnenberg AD (2005) Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 45(8):872–877
Szakacs G et al (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219–234
Bleau AM et al (2009) PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4(3):226–235
Hambardzumyan D, Squatrito M, Holland EC (2006) Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10(6):454–456
Deleyrolle LP et al (2011) Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain 134(Pt 5):1331–1343
Zeng L et al (2016) Label-retaining assay enriches tumor-initiating cells in glioblastoma spheres cultivated in serum-free medium. Oncol Lett 12(2):815–824
Acknowledgements
Grant Support: NINDS (National Institue of Neurological Disorders and Stroke) grant NS052563 and The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ludwig, K., Kornblum, H.I. Molecular markers in glioma. J Neurooncol 134, 505–512 (2017). https://doi.org/10.1007/s11060-017-2379-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-017-2379-y